Ras Peptide VAL
A synthetic form of the Ras peptide containing a point mutation at position 12 (glycine to valine) with potential antineoplastic activity. Vaccination with this peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this Ras mutation, resulting in decreased tumor growth. (NCI04) [ ]
Term info
Ras Peptide VAL
- Ras Peptide VAL
NCIT_C128784, NCIT_C157711, NCIT_C157712
Ras_Peptide_VAL
665824
Ras Peptide VAL
Pharmacologic Substance, Amino Acid, Peptide, or Protein
C1514730
C2804
Term relations
- Mutated Ras Peptide
- Chemical_Or_Drug_Has_Physiologic_Effect some T-Cell Activation
- Chemical_Or_Drug_Has_Physiologic_Effect some Inhibition of Cell Proliferation
- Chemical_Or_Drug_Affects_Cell_Type_Or_Tissue some Cytotoxic T-Lymphocyte
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Antigen Sensitization
- Chemical_Or_Drug_Has_Physiologic_Effect some Immunopotentiation